September 23, 2024 - The clinical trial application (IND) for Pan-KRAS inhibitor JAB-23E73 independently developed by JACOBIO was approved in the United States, and a Phase I/IIa clinical trial for advanced solid tumors will be conducted in the United States. The IND application for China has been submitted, and clinical trials will be conducted in China simultaneously after approval.

KRAS is widely present in a variety of tumor mutations. 23%-25% of cancer patients have KRAS mutations. About 2.7 million new tumor patients with KRAS-related mutations each year are expected to benefit from Pan-KRAS inhibitors.

JAB-23E73 can inhibit both active and inactive KRAS, and has no significant inhibition on HRAS and NRAS. As an oral KRAS inhibitor, JAB-23E73's preclinical data showed good pharmacokinetic properties.

JACOBIO is committed to providing patients with breakthrough treatment options. The company's research projects are based on the six major tumor signaling pathways of KRAS, tumor immunity, tumor metabolism, P53, RB, and MYC, and the core projects aim to be the top three in the world.

The company's vision is to work with partners to become a globally recognized leader in drug development. Jacobs' laboratories are located in Beijing, Shanghai, China and Boston, USA, with an induced allosteric drug discovery platform and an iADC drug development platform.

https://news.yaozh.com/archive/44249.html